Abstract
Objective Cytokine storm and coagulopathy being the major causes of morbidity in Covid-19 patients, based on an earlier pilot study yielding control of IL-6 and D-Dimer, when AFO-202 and N-163 strains of Aureobasidium Pullulans produced beta glucans, were studied separately and in combination for 30 days. In this study, we evaluated the efficiency of the two variants’ combinations in comparison with the control arm, which underwent a conventional regimen of treatment alone, for a shorter duration.
Methods A total of 40 RT-PCR positive Covid-19 patients divided into two groups (Gr): Gr. 1 control (n=22) – Standard treatment; Gr. 2 (n =18) – Standard treatment + combination of AFO-202 and N-163 beta glucans for 15 days. Biomarkers of relevance to cytokine storm and coagulopathy were evaluated at baseline on Day 7 and Day 15.
Results The C-reactive protein (CRP), which declined from 33.95 ng/ml to 5.07 ng/ml in control and from 33.95 ng/ml to 5.64 ng/ml in the treatment arm on Day 7, increased to 14.6 ng/ml in the former while it continued to be under control in the treatment arm at 5.68 ng/ml on Day 15. The same trend was observed in Ferritin, whose values were 560.58 pg/ml at baseline to 261.44 pg/ml (day-7) and 182.40 pg/ml (day-15) in the treatment group, while it was 535.24 pg/ml at baseline, 116.66 pg/ml on day 7 and 291.95 pg/ml on day 15 in the control group. IL-6 showed a higher decrease in treatment group compared to the control group. The difference between day 7 and day 15 values were statically significant.
Conclusion A statistically significant control of IL-6, CRP and Ferritin in Covid-19 patients who orally consumed AFO-202 and N-163 strains of Aureobasidium Pullulans produced Beta glucans together in 15 days make us recommend this safe food supplement be consumed by Covid-19 patients along with conventional treatments, especially to the vulnerable population, as a prophylaxis amidst the prolonged pandemic with evolution of mutated strains of SARS-COV2.
Competing Interest Statement
Author Samuel Abraham is a shareholder in GN Corporation, Japan which in turn is a shareholder in the manufacturing company of the Beta Glucans described in the study.
Clinical Trial
The study was registered in Clinical trials registry of India, CTRI/2021/10/037380
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Ethics Committee (IEC) of Madras Medical College, India on 15th September, 2021.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
(pushkala66m{at}gmail.com)
(sesh2525{at}gmail.com)
(deanmmc{at}tn.gov.in)
(drsudha87{at}ymail.com)
(drkraghavan{at}nichimail.jp)
(dedeepiya_76{at}yahoo.co.in)
(nikewaki{at}phoenix.ac.jp)
(miwasaki{at}yamanashi.ac.jp)
(drspp{at}nichimail.jp)
(drsam{at}nichimail.jp)
Conflicts of interest/Competing interests: Author Samuel Abraham is a shareholder in GN Corporation, Japan which in turn is a shareholder in the manufacturing company of the Beta Glucans described in the study.
Funding: No external funding was received for the study
Ethics Approval: The study was registered in Clinical trials registry of India, CTRI/2021/10/037380. The study was approved by the Institutional Ethics Committee (IEC) of Madras Medical College, India on 15th September, 2021.
Data Availability
All data produced in the present work are contained in the manuscript
